Source comparison
CJC-1295 no DAC with Alcohol Safety: Interaction Comparison
0 drinks (abstinent baseline) 0% N/A 100% baseline response Predictable first-order kinetics Optimal protocol conditions. No interaction risk 1 standard drink (14g ethanol) 15–25% reduction in pulse amplitude 6–8 hours 75–85% of expected GH output Minimal comp
This comparison does not assign a generated winner or score.
- 0 drinks (abstinent baseline)
- 0%
- N/A
- 100% baseline response
- Predictable first-order kinetics
- Optimal protocol conditions. No interaction risk
- 1 standard drink (14g ethanol)
- 15–25% reduction in pulse amplitude
- 6–8 hours
- 75–85% of expected GH output
- Minimal competition, slight延迟 in peptide clearance
- Low impact if administered >12 hours post-drink
- 2–3 standard drinks
- 50–70% reduction
- 12–18 hours
- 30–50% of expected output
- Moderate enzyme competition, clearance延迟 by 20–40%
- Significant blunting. Avoid peptide use within 24 hours
- 4–5 standard drinks (binge threshold)
- 75–85% reduction
- 18–24 hours with 12-hour residual
- <20% of expected output
- Severe saturation of hepatic pathways, unpredictable kinetics
- Near-complete antagonism. Peptide administration pointless for 48 hours
- Chronic use (>14 drinks/week)
- Baseline GH pulsatility reduced 30–40%
- Persistent (chronic neuroendocrine suppression)
- Progressive receptor downregulation reduces response over weeks
- CYP3A4 induction accelerates peptide clearance but impairs IGF-1 synthesis
- Protocol failure likely. Alcohol use incompatible with sustained GH secretagogue efficacy
- Acute intoxication (BAC >0.08%)
- >80% suppression during intoxication
- 24+ hours total (intoxication + recovery)
- Functionally zero. Pituitary unresponsive
- Complete metabolic priority to ethanol, peptide clearance undefined
- Do not administer peptide. Wasted dose with no therapeutic benefit